Dianthus Therapeutics to Present Claseprubart Data at AANEM 2026 — Dianthus Therapeutics, Inc.

Event summary

Dianthus Therapeutics plans one oral and four poster presentations on claseprubart at the 2026 AANEM Annual Meeting.
Interim data from the Phase 3 CAPTIVATE trial shows a 75% response rate in CIDP patients.
Phase 2 MaGic open-label extension data highlights sustained efficacy and favorable safety profile in gMG.
Claseprubart was granted Orphan Drug Designation by the FDA for Myasthenia Gravis in May 2026.

The big picture

Dianthus Therapeutics is positioning claseprubart as a potential best-in-disease treatment for severe autoimmune disorders, leveraging its selective targeting of the classical complement pathway. The upcoming data presentations at AANEM 2026 are critical for validating its clinical profile against existing therapies like IVIG. The company's strategy hinges on demonstrating consistent efficacy and safety across multiple indications to justify its pipeline-in-a-product approach.

What we're watching

Clinical Efficacy: How the 75% response rate in CIDP patients will impact regulatory approval timelines.
Market Differentiation: Whether claseprubart's selective inhibition of the classical complement pathway can reduce infection risks compared to existing therapies.
Pipeline Progress: The pace at which Dianthus can advance claseprubart through additional trials in Multifocal Motor Neuropathy and generalized Myasthenia Gravis.